Q2 Earnings Forecast for AVDL Issued By Lifesci Capital

Key Points

• Lifesci Capital recently issued its Q2 2026 earnings forecast for Avadel Pharmaceuticals, projecting $0.19 earnings per share for the quarter, while maintaining a "Strong-Buy" rating on the stock.
• Avadel's stock price is currently trading around $14.66, with an average target price of $19.14 as assigned by analysts, indicating a potential upside.
• In its latest earnings report for Q2, Avadel Pharmaceuticals beat expectations with earnings of $0.10 per share and a revenue increase of 64.1% year-over-year.

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL - Free Report) - Analysts at Lifesci Capital issued their Q2 2026 earnings per share estimates for shares of Avadel Pharmaceuticals in a report issued on Wednesday, September 3rd. Lifesci Capital analyst F. Brisebois expects that the company will post earnings of $0.19 per share for the quarter. Lifesci Capital has a "Strong-Buy" rating on the stock. The consensus estimate for Avadel Pharmaceuticals' current full-year earnings is ($0.51) per share. Lifesci Capital also issued estimates for Avadel Pharmaceuticals' Q3 2026 earnings at $0.23 EPS, Q4 2026 earnings at $0.23 EPS and FY2026 earnings at $0.73 EPS.

A number of other equities analysts have also recently issued reports on AVDL. Zacks Research upgraded Avadel Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 8th. Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of Avadel Pharmaceuticals in a research note on Friday, August 8th. UBS Group upped their target price on Avadel Pharmaceuticals from $13.00 to $20.00 and gave the company a "buy" rating in a research report on Thursday, August 21st. Wall Street Zen raised Avadel Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $19.00 price objective on shares of Avadel Pharmaceuticals in a report on Thursday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, Avadel Pharmaceuticals presently has an average rating of "Buy" and an average price target of $19.14.

Avadel Pharmaceuticals Stock Performance

NASDAQ AVDL opened at $14.66 on Thursday. The company has a market cap of $1.42 billion, a P/E ratio of -488.67 and a beta of 1.58. The business's 50 day moving average price is $11.75 and its 200-day moving average price is $9.65. Avadel Pharmaceuticals has a fifty-two week low of $6.38 and a fifty-two week high of $16.66.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.08. The firm had revenue of $68.13 million for the quarter, compared to the consensus estimate of $60.28 million. Avadel Pharmaceuticals had a negative return on equity of 3.73% and a negative net margin of 1.32%.The company's revenue for the quarter was up 64.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.14) EPS. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On Avadel Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC increased its holdings in shares of Avadel Pharmaceuticals by 217.5% in the second quarter. Tower Research Capital LLC TRC now owns 8,795 shares of the company's stock valued at $78,000 after purchasing an additional 6,025 shares during the last quarter. Krensavage Asset Management LLC raised its position in Avadel Pharmaceuticals by 0.9% in the second quarter. Krensavage Asset Management LLC now owns 958,877 shares of the company's stock valued at $8,486,000 after purchasing an additional 8,877 shares during the period. MML Investors Services LLC raised its position in Avadel Pharmaceuticals by 6.7% in the second quarter. MML Investors Services LLC now owns 207,378 shares of the company's stock valued at $1,835,000 after purchasing an additional 13,072 shares during the period. Man Group plc raised its position in Avadel Pharmaceuticals by 101.3% in the second quarter. Man Group plc now owns 57,931 shares of the company's stock valued at $513,000 after purchasing an additional 29,149 shares during the period. Finally, BNP Paribas Financial Markets raised its position in Avadel Pharmaceuticals by 30.8% in the second quarter. BNP Paribas Financial Markets now owns 22,823 shares of the company's stock valued at $202,000 after purchasing an additional 5,372 shares during the period. Institutional investors and hedge funds own 69.19% of the company's stock.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.